MedTrace Logo

An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors

NCT05274191 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-03-10

No results posted yet for this study

Summary

A single arm, open-label Phase II clinical study.The subjects were patients with lung, gastric and colorectal cancers.

Conditions

Interventions

DRUG

Pyrotinib Maleate

Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;

OTHER

standard regimen

standard regimen

Sponsors & Collaborators

  • Zhongshan Hospital Xiamen University

    lead OTHER

Principal Investigators

  • li xiao · Zhongshan Hospital Affiliated to Xiamen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-04
Primary Completion
2022-03-15
Completion
2024-03-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05274191 on ClinicalTrials.gov